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ABSTRACT 
Programmed Cell Death-1 (PD-1) is an inhibitory co-receptor on immune cells, and is 
essential for self-tolerance, as mice genetically lacking PD-1 (PD-1-/-) develop 
spontaneous autoimmune diseases. PD-1-/- mice are also susceptible to severe 
experimental autoimmune encephalomyelitis (EAE), characterized by a massive 
production of effector/memory T cells against myelin auto-antigen, the mechanism of 
which is not fully understood. We found that an increased primary response of PD-1-/- 
mice to heat-killed mycobacteria (HKMTB), an adjuvant for EAE, contributed to the 
enhanced production of T-helper 17 (Th17) cells. Splenocytes from HKMTB-immunized, 
lymphocyte-deficient PD-1-/- RAG2-/- mice were found to drive antigen-specific Th17 
cell differentiation more efficiently than splenocytes from HKMTB-immunized PD-1+/+ 
RAG2-/- mice. This result suggested PD-1’s involvement in the regulation of innate 
immune responses. Mice reconstituted with PD-1-/- RAG2-/- bone marrow and PD-1+/+  
CD4+ T cells developed more severe EAE, compared to the ones reconstituted with PD-
1+/+ RAG2-/- bone marrow and PD-1+/+ CD4+ T cells. We found that, upon recognition of 
HKMTB, CD11b+ macrophages from PD-1-/- mice produced very high levels of IL-6, 
which helped promote naïve CD4+ T cell differentiation into IL-17-producing cells. We 
propose a model in which PD-1 negatively regulates anti-mycobacterial responses by 
suppressing innate immune cells, which in turn prevents auto-reactive T cell priming and 
differentiation to inflammatory effector T cells. 
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INTRODUCTION 
Autoimmune disease development is impacted by both genetic and environmental factors. 
Programmed death (PD)-1 is a type-I membrane protein that delivers inhibitory signals to 
immune cells upon the binding of its ligand, PD-L1 or PD-L2 (1). PD-1 has been shown 
to be important for self-tolerance, since spontaneous autoimmune diseases develop in 
PD-1-/- mice (2-4). A single nucleotide polymorphism that affects PD-1 expression is 
associated with autoimmune diseases in humans, such as systemic lupus erythematosus 
(5), type I diabetes (6), rheumatoid arthritis (7), and multiple sclerosis (MS) (8), 
suggesting that PD-1 deficiency may be a genetic factor involved in the development of  
autoimmunity. 
Experimental autoimmune encephalomyelitis (EAE) is a rodent model of T cell-
mediated inflammatory disease in the central nervous system (CNS), causing 
demyelination, axonal damage and paralysis, and is a commonly used model for human 
MS. Previous reports suggested that PD-1 functions to attenuate EAE. PD-1 and its 
ligands were found to be strongly expressed on immune infiltrates in the CNS during the 
peak phase of EAE (9-11). In EAE studies, PD-1-deficient mice or the use of blocking 
antibodies that inhibit PD-1 engagement by ligands resulted in earlier disease onset, 
increased inflammatory infiltrates, and increased severity of clinical symptoms when 
compared to normal disease progression (10-16). It has been demonstrated that ligand 
engagement of PD-1 inhibits T cell activation, expansion, and cytokine production (17-
19). Similarly, in EAE, PD-1 signaling in CNS-specific helper T cells may inhibit their 
expansion and secretion of inflammatory cytokines (10-12).  Recently T-helper 17 (Th17) 
cells were shown to be involved in EAE, by producing IL-17 and GM-CSF (20, 21). Two 
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reports showed that PD-1-/- mice mount an augmented Th17 response to EAE induction 
(14, 16). However, the fundamental mechanisms by which PD-1 regulates antigen-
specific Th17 cell differentiation, expansion, and effector function in EAE remain to be 
understood.  
To induce EAE, mice are immunized with myelin auto-antigens in an emulsion of 
mycobacterium tuberculosis (MTB)-derived adjuvants, causing a strong innate 
inflammatory response, leading to Th skewing (22). Curiously, recent studies showed that 
PD-1-/- mice exhibited an altered response to infection with mycobacteria, characterized 
by uncontrolled bacterial burden, massive production of cytokines, termed “cytokine 
storm,” and early death (23-25). We wondered if this unique response of PD-1-/- mice to 
mycobacteria contributed to their Th response in EAE. 
 In this study, we took a combination of genetic and immunological approaches in 
which the innate response to MTB-derived adjuvant and antigen-specific T cell 
polarization were separately analyzed. The present data suggest that an enhanced innate 
response of PD-1-/- mice to MTB contribute to the susceptibility of these mice to severe 
EAE. We propose a novel function of PD-1 in controlling the basal state of the innate 




Augmented EAE with sub-optimal immunization of PD-1-/- mice. 
EAE in C57BL/6 mice is typically induced by immunizing the mice with MOG35-55 
peptide in an emulsion of CFA and 200-300 µg of additional heat-killed MTB (HKMTB), 
followed by two separate intraperitoneal injections of pertussis toxin (PTX), which is 
assumed to induce a strong innate immune response leading to MOG-specific T-cell 
priming. In agreement with previous reports (12, 14), the induction of EAE with this 
treatment resulted in accelerated disease progression in PD-1-/- mice, characterized by 
earlier disease onset and an earlier peak in disease activity (Fig. 1A).  
Since this treatment also caused prominent disease in PD-1+/+ mice, we next examined 
the effects of suboptimal immunization with reduced adjuvants on both wild-type and 
mutant mice. PD-1-/- mice appeared to be susceptible to EAE by the suboptimal treatment. 
First, when PTX injection was eliminated from the treatment, the PD-1-/- mice developed 
a comparable disease as with full immunization, whereas PD-1+/+ mice showed an 
attenuated response (Fig. 1B). PTX is known to open the blood brain barrier (26), inhibit 
Foxp3 expression on T cells (27), and enhance Th17 development in EAE (28). Our 
findings and a previous study by others (29) indicated that PTX is dispensable for the 
development of EAE in PD-1-/- mice. Next, when both PTX and the additional dose of 
HKMTB were eliminated, many PD-1-/- mice still developed EAE, while the PD-1+/+ 
mice remained healthy (Fig. 1C). The severe EAE in PD-1-/- was well-correlated with the 
number of immune cells infiltrating in the affected brain (Fig. S1). 
CFA itself contains a low dose of HKMTB (50 µg/mouse). This small dose of HKMTB 
appeared to be required for EAE in PD-1-/- mice, because PD-1-/- mice that received MOG 
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in incomplete Freund’s adjuvant did not develop EAE with or without PTX. These data 
indicated that PD-1-/- mice were susceptible to EAE by immunization with much lower 
doses of adjuvants. 
 
Enhanced inflammatory cytokine production associates with EAE in PD-1-/- mice.  
Th1 and Th17 cells, which typically produce IFN−γ and IL-17, respectively, have been 
shown to be involved in EAE (30). To study the development of the two Th cell types 
during disease progression in PD-1-/- mice, we analyzed the MOG-specific effector T cell 
response at early and later phases of the disease. On day 8, purified CD4+ T cells from 
the spleen of PD-1-/- mice produced significantly more IL-17 and IFN-γ than the cells 
from PD-1+/+ mice, upon re-stimulation with MOG35-55 in vitro (Fig. 2A). In response to 
suboptimal immunization conditions, the cytokine levels were lower, but the difference 
between PD-1-/- and PD-1+/+ mice was still significant. These findings were consistent 
with the earlier onset, and the severe disease in PD-1-/- mice. 
Next, we examined the T cell responses to MOG35-55 on day 30, when the clinical 
symptoms have mostly receded. As shown in Fig. 2B, the PD-1-/- CD4+ cells still 
produced significantly higher levels of IL-17 than PD-1+/+ control cells; however, the 
IFN−γ levels were indistinguishable. These results suggested that, in comparison to PD-
1+/+ mice, PD-1-/- mice generated a stronger memory response to both the standard and 
suboptimal EAE-inducing immunizations, and this response was associated with 
enhanced IL-17 production. 
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The innate response to HKMTB in PD-1-/- mice influences antigen-specific Th17 
development. 
 
Since PD-1-/- mice developed a MOG35-55-specific Th17 response to EAE immunizations 
with low doses of HKMTB, PD-1-/- mice may have intrinsic properties to exhibit 
augmented response to HKMTB, which results in enhanced induction of Th17. As PD-1 
is expressed on innate cells (31, 32) as well as T and B cells, PD-1 may regulate innate 
response that influences T cell activation. To address this point, we established a system 
in which we can separately evaluate the function of PD-1 in the innate and the acquired 
immune responses. First, we bred PD-1-/- mice onto the RAG2-/- background to exclude T 
and B cell responses (see Materials and Methods). Then, PD-1-/- RAG2-/-or control PD-
1+/+ RAG2-/- mice were immunized with HKMTB alone in CFA to induce a genuine anti-
HKMTB response in vivo. Spleen cells from the immunized mice were prepared and 
used to stimulate naïve OVA-specific TCR transgenic T cells (PD-1+/+) under the various 
Th skewing conditions (see Materials and Methods).  
We found that, when splenocytes from HKMTB-immunized PD-1-/- RAG2-/-mice were 
incubated with PD-1+/+ naïve OVA-reactive T cells under neutral condition, IL-17+ cells 
were produced more efficiently (average±SD of 22.5±3.627%) than when splenocytes 
from HKMTB-immunized PD-1+/+ RAG2-/- mice (13.4±4.68%) were used (Fig3A 2nd 
columns; P=0.021 from 5 combined experiments). When exogenous IL-6 and TGF-β are 
added to the neutral condition (Th17 condition; Fig3A 4th columns), splenocytes from 
both background showed efficient induction of IL-17+ cells (PD-1+/+ RAG2-/- vs. PD-1-/- 
RAG2-/- :  34.33 ±3.99  vs. 37.43±5.84, P=0.54). In contrast, splenocytes from both PD-
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1+/+ RAG2-/- and PD-1-/- RAG2-/- mice were similarly efficient in promoting the 
differentiation of IFN−γ-producing cells under Th1 skewing conditions (P=0.48 in no 
immunized and P=0.65 in immunized mice; 5 experiments) (Fig. 3B). We got essentially 
same data when we performed the same experiments with the mice in different genetic 
background (using PD-1-/- RAG2-/- in BALB/c background and naïve CD4+ cells from 
DO11.10 TCR Tg), suggesting the finding is general to PD-1-/- strain (Fig. S2). Also, 
splenocytes from HKMTB immunized PD-1-/- mice on RAG2-sufficient background 
were more potent in inducing Th17 than PD-1+/+ counterpart (Fig. S3).  It should be noted, 
however, that exogenous IL-6 and TGF-β were required for efficient Th17 induction 
(Th17 condition) when RAG2-sufficient splenocytes were used. It suggested that T cell 
and B cell responses in RAG2-sufficient mice somehow attenuate the primary innate anti-
HKMTB-response.  In any case, the current results indicated that the innate immune 
response of PD-1-/- mice, when exposed to mycobacteria, were more efficient at 
promoting a Th17 response, compared to PD-1+/+ mice. 
 
Innate immune cells of PD-1-/- mice causes enhanced Th17 and exacerbation of EAE  
To directly determine contribution of enhanced innate response of PD-1-/- mice to 
HKMTB in the development of EAE, we reconstituted lethally irradiated wild-type 
C57BL/6 mice with bone marrow cells from PD-1+/+ RAG2-/- and PD-1-/- RAG2-/- mice. 
Then, recipients received adoptive transfer of CD4+ T cell from PD-1+/+ and were 
immunized with MOG35-55 in the emulsion with CFA and HKMTB. We found that the 
mice reconstituted with PD-1-/- RAG2-/- bone marrow developed EAE with earlier onset 
and more severe clinical scores than the mice reconstituted with PD-1+/+ RAG2-/- bone 
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marrow (Fig. 4A). The severe EAE in the PD-1-/- RAG2-/- bone marrow recipients were 
associated with significantly higher production of IL-17 in the recall response, compared 
to  PD-1+/+ RAG2-/- recipients (Fig. 4B). The data strongly suggested that PD-1 
deficiency in the innate cells caused priming of CD4+ T cell from PD-1+/+ into pathogenic 
Th17, leading to severe EAE.  
 
CD11b+ macrophages from HKMTB-treated PD-1-/- mice efficiently induce Th17 
cell polarization 
We wanted to determine the innate immune cell population responsible for the enhanced 
Th17 induction in PD-1-/- mice. Since macrophages and some dendritic cells (DCs) 
express CD11b, we magnetically separated PD-1-/- splenocytes into the CD11b+ and 
CD11b- populations, treated each of them with HKMTB in vitro, and then assayed their 
ability to induce Th17. We found that the CD11b+ population from PD-1-/- mice skewed 
naïve T cells into Th17 cells more efficiently than did CD11b+ cells from PD-1+/+ mice, 
in a manner dependent on the added bacterial dose (Fig. 5A and 5B). In contrast, we 
detected little or no Th17 skewing by the CD11b- population (Fig. 5B), suggesting that 
the antigen presenting cell (APC)s in the CD11b- fraction (mostly B cells) were not 
involved in the Th17 skewing by PD-1-/- APCs. Further FACS-sorting of CD11b+ 
population into macrophage (CD11b+) and DCs (CD11b+ CD11c+) revealed that 
HKMTB-treated macrophages, but not of HKMTB-treated DCs promote Th17 skewing 
(Fig S4). Similar results were obtained when CD11b+ cells were prepared from PD-1+/+ 
RAG2-/- and PD-1-/- RAG2-/- mice (Fig. 5C). These data suggested that CD11b+ 




Enhanced production of IL-6 by CD11b+ cells from PD-1-/- mice causes strong Th17 
development  
To examine the mechanism of the enhanced Th17 skewing by PD-1-/- macrophages, we 
measured the cytokine production from the CD11b+ population from PD-1-/- mice after 
HKMTB treatment. Among the cytokines tested (IL-2, IL-4, TNF-α, IL-6, IL-17, IFN-γ, 
IL-10, IL-12 and IL-23), the PD-1-/- CD11b+ cells produced more IL-6 in the presence of 
HKMTB than did the PD-1+/+ CD11b+ cells (Fig. 6A). Other cytokines detected, such as 
TNF-α (Fig. 6B) and IL-10 (Fig. 6C), were similar between CD11b+ cells from PD-1+/+ 
and PD-1-/- cells. In addition, this augmentation of IL-6 production by PD-1-/- cells was 
specific for HKMTB, as other gram-positive bacteria such as heat-killed listeria 
monocytogenes (HKLM), did not induce the production of significant levels of IL-6 from 
either PD-1+/+ or PD-1-/- CD11b+ cells (Fig. 6A). The difference in IL-6 production 
between bacterial strains may be due to differences in their ability to activate toll-like 
receptors, as well as other receptors, such as dectin, on the CD11b+ cells.  
Since IL-6 is important for Th17 induction, we confirmed that the IL-6 from 
HKMTB-treated PD-1-/- CD11b+ cells functioned to induce the differentiation of IL-17-
producing cells. As shown in Fig. 6D, the antigen-specific Th17 differentiation by 
HKMTB-treated CD11b+ cells was inhibited in the presence of a blocking anti-IL-6 
receptor antibody, in a dose-dependent manner. Taken together, these data suggested that 




Here we found that the induction of EAE in PD-1-/- mice required considerably lower 
amounts of bacterial adjuvants compared to the EAE induction in PD-1+/+ mice. In 
addition, PD-1-/- mice mounted an augmented Th-17 effector/memory response against 
myelin antigen. Although PD-1 has previously been shown to function on T cells, our in 
vitro and in vivo assays using naïve PD-1+/+ T cells and lymphocyte-null PD-1-/- RAG2-/- 
mice suggested that PD-1 regulates Th17 differentiation indirectly, by suppressing the IL-
6 production from innate immune cells. 
Previous studies have shown that IL-6 is necessary for Th17 induction in EAE, as  
IL-6-/- mice (33) or treatment with an IL-6 blocking antibody (34) abrogates EAE. 
Although activated T cells can produce autocrine IL-6, the receptor for IL-6 is expressed 
only on naïve T cells and is down-modulated after activation (35, 36). Thus, T cells that 
are exposed to IL-6 early in their activation differentiate into pathogenic Th17 cells. Our 
experiments showed macrophages, but not DCs from PD-1-/- enhanced the induction of 
Th17 upon HKMTB treatment in vitro (Fig. S4). DCs are necessary for EAE 
development, but are not potent to produce IL-6 upon mycobacteria recognition at least in 
vitro (37, 38). Thus, although our data does not exclude PD-1’s function on DCs in vivo, 
it suggest that CD11b+ macrophages are primary population that produces early IL-6 in 
response to HKMTB. 
The massive production of IL-6 by PD-1-/- macrophages may explain the unique 
response of these mice to mycobacterial infection. Although the Th1 response is ideal for 
controlling MTB (39), infected PD-1-/- mice exhibit high serum IL-6 levels (23, 24), 
which may lead to an altered Th1 response and an augmented Th17 response. An 
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augmented Th17 response induced by over-produced IL-6 not only inhibits efficient anti-
mycobacterial immune responses, but also contributes to autoimmune-like diseases in 
mice. We conclude that PD-1 functions to control innate IL-6 production, which in turn 
suppresses auto-antigen-specific T cell responses. Our conclusions are consistent with a 
previous report that immunizing PD-1-/- mice with Bacille Calmette-Guerin (BCG) 
induces symptoms resembling Kawasaki disease, a vascular inflammatory disease 
associated with IL-6 production (40).  
As PD-1 down-modulates the tyrosine phosphorylation of cytoplasmic proteins 
including Syk tyrosine kinase, through activation of non-receptor tyrosine phosphatase, 
SHP-2 (41), a direct function of PD-1 in macrophage activation could explain the 
augmented IL-6 production by PD-1-/- macrophages. However, we could not demonstrate 
the expression of PD-1 on the monocyte/macrophage population. This inability to 
reproduce results from a previous study in which PD-1 was detected on macrophages (32, 
42) may be due to the high background binding of available anti-mouse PD-1 antibodies 
to this cell type. Indeed, the mAb used in previous research (42) was found to stain PD-1-
/- macrophages as efficiently as PD-1+/+ macrophages (our unpublished data). Thus, it is 
likely that the regulation of macrophage activation by PD-1 is not intrinsic to the 
macrophage. Since basal macrophage activation occurred in PD-1-/- RAG2-/- mice, this 
would suggest that non-T cells, possibly innate lymphoid cells, are responsible for the 
basal macrophage activation in these mice. For example, PD-1 is expressed on natural 
killer cells (ref (43) and our unpublished data) and regulates their cytokine production 
(44). In the absence of PD-1, natural killer cells may produce more cytokines during 
immune surveillance or upon infection, possibly affecting the activation status of 
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macrophages. How PD-1 regulates macrophage activation in cell-extrinsic manner is 
currently unclear and should be addressed in future studies. 
In conclusion, we propose that PD-1 can regulate a magnitude of primary innate 
responses to certain microbes, and this regulation in turn inhibit the differentiation of self 
antigen-specific inflammatory T cells. Our findings provide a new perspective on the 
function of PD-1, which was previously well-established as a key molecule for the 
maintenance of immune tolerance.  
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MATERIALS AND METHODS 
Mice. PD-1-/- mice were described before (45) and thoroughly backcrossed into C57BL/6 
or BALB/c background (for 13 times). PD-1-/- and the littermate control (PD-1+/+) were 
obtained from heterozygote (PD-1+/-) to heterozygote breeding. DO11.10 TCR transgenic 
(Tg) mice and OT-II TCR Tg mice were obtained from Drs. K. Murphy (Washington 
University,  St. Louis, MO) and K. Kabashima (Kyoto University, Japan), respectively. 
RAG2-/- mice were from Dr. F. Alt (Harvard Medical School, Boston, MA) and 
backcrossed into BALB/c or C57BL/6 background for 10 times. To generate mice doubly 
deficient for PD-1 and RAG2, we first mated PD-1 single KO with RAG2 single KO in 
the same genetic background. Resulting F1 generation (PD-1+/- RAG2+/-) was 
intercrossed to obtain PD-1-/- RAG2-/- (double KO). Littermate PD-1+/+ RAG2-/- mice 
from the intercross breeding were used as control. All mice were maintained under 
specific pathogen-free conditions and treated according to approved protocols by the 
Animal Research Committee, Graduate School of Medicine, Kyoto University. 
 
Reagents. Neutralizing rat anti-IL-6 mAb (MR16-1) was kindly provided by Dr. T. 
Kishimoto (Osaka University, Japan) and Chugai Pharmaceutical Co. Ltd (Tokyo, Japan). 
Chrompure Rat immunoglobulin G (IgG) was from Jackson Immuno Research (West 




EAE. Mice in were immunized subcutaneously with 0.2 ml of an emulsion containing 
200 µg MOG35-55 peptide, CFA, and 250 µg HKMTB. In addition, the mice received two 
intraperitoneal injections of 200 ng PTX at the time of, and 48 hours after immunization. 
In some experiments, “suboptimal” immunization conditions were used, in which 
HKMTB, PTX, or both were excluded. Mice were observed daily for clinical signs of 
disease, and EAE scores defined as follows: 0, no disease; 1, limp tail; 2, hind limb 
weakness; 3, paralysis of one hind limb; 4, paralysis of both hind limbs; 5, limited 
movement; 6, moribund or death. Scores are shown as the mean clinical scores for each 
experimental group. For re-stimulation assay, spleens were harvested 8 or 30 days after 
immunization, and CD4+ T cell- enriched samples were obtained using anti-CD4 
microbeads and the autoMACS system (Miltenyi). In a 1-ml volume, 2 × 106 of the 
isolated CD4+ T cells were cultured with 2 × 106 mitomycin C-treated splenocytes from 
PD-1+/+ mice in the presence of MOG35-55 peptide (30 µg/ml). Supernatants were 
harvested 3 days later for cytokine analysis.  
 
Antigen-specific Th skewing by HKMTB-immunized splenocytes. Mice were 
immunized subcutaneously with 0.2 ml of an emulsion containing 250 µg HKMTB and 
CFA. Eight days later, 1 × 106 splenocytes were cultured with 1 × 105 CD4+ T cells 
purified from DO11.10 or OTII TCR Tg mice in the presence of 5 µg/ml OVA in 48-well 
plates. For Th-skewing, the following recombinant cytokines and antibodies were added 
to the cultures: Th1: IL-12 (20 ng/ml) and anti-IL-4 (10 µg/ml); Th17: human TGF-β1 (5 
ng/ml), IL-6 (20 ng/ml), anti-IL-4 (10 µg/ml), and anti- IFN−γ (10 µg/ml); neutral 
conditions: anti-IL-4 (10 µg/ml) and anti-IFN−γ (10 µg/ml). Four days later, the cells 
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were re-stimulated with 10 ng/ml PMA and 1 µg/ml Ionomycin (Sigma-Aldrich) in the 
presence of 0.66 µl/ml BD Golgistop for 6 hours. After stimulation, the cells were 
washed in FACS buffer (PBS, 2% FCS, and 0.02% NaN3) and stained for cell-surface 
markers. The cells were then treated with BD Cytofix/Cytoperm buffer, washed with BD 
perm/wash buffer twice, and subsequently stained with anti-cytokine antibodies. Samples 
were analyzed by FACSCanto II (BD). 
 
Antigen-specific Th skewing by mycobacteria activated CD11b+ cells. Splenocytes 
were labeled with Miltenyi CD11b microbeads and subjected to 3 positive selections by 
autoMACS (Miltenyi). The purified cells contained approximately 95% CD11b+ cells. In 
a total volume of 200 µl, 3 × 105 of the isolated CD11b+ cells were stimulated with 
HKMTB or HKLM at 10 and 100 µg/ml. Three days later, cell culture supernatants were 
evaluated for cytokine production. For antigen-specific Th skewing, 1 × 106 CD11b+ cells 
were stimulated with HKMTB or HKLM at 10 and 100 µg/ml for 3 days. The stimulated 
CD11b+ cells were then cultured with 1 × 105 CD4+ T cells purified from OTII TCR Tg 
mice for 4 days in the presence of 5 µg/ml OVA323–339 under neutral conditions. In some 
experiments, a rat anti-IL-6R blocking antibody or control rat IgG was added to the 
cultures. After a 4-day incubation, the development of Th1 and Th17 cells was examined 
by intracellular cytokine staining, as described above. 
 
Cytokine analysis. Culture supernatants were stored at -80°c until the analysis. IL-12p70 
and IL-23 (p19/p40) were determined by ELISA (eBioscience). The IL-2, IL-4, TNF-α, 
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IL-10, IL-6, IL-17 and IFN-γ levels were measured by the mouse Th1/Th2/Th17 CBA kit 
(BD) or ELISA (eBioscience), according to the manufacturer’s protocols. 
 
Statistics. Statistical significance between two groups was calculated using a two-tailed 
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FIGURE LEGENDS 
Fig. 1. Augmented EAE with sub-optimal immunization of PD-1-/- mice. (A) EAE 
scores of PD-1+/+ (n=12) and PD-1-/- (n=12) mice (C57BL/6 background) after 
immunization with MOG/CFA/HKMTB in the presence of PTX on day 0 and day 2. (B) 
EAE scores of PD-1+/+ (n=13) and PD-1-/- (n=12) mice after immunization with 
MOG/CFA/HKMTB. (C) EAE scores of PD-1+/+ (n=13) and PD-1-/- (n=11) mice after 
immunization with MOG/CFA. Data presented are combined from two independent 
 22 
experiments (means±SEM). Statistical analysis was performed using a two-tailed 
Student’s t-test. * P<0.05, and ** P<0.01.  
 
Fig. 2. EAE in PD-1-/- mice associates with enhanced inflammatory cytokine 
production. (A) PD-1+/+ and PD-1-/- mice (C57BL/6 background) were immunized with 
MOG/CFA/HKMTB/PTX (n=12), MOG/CFA/HKMTB (n=11), or MOG/CFA (n=6) and 
analyzed 8 days later. (B) PD-1+/+ and PD-1-/- mice were immunized with 
MOG/CFA/HKMTB/PTX (n=7), MOG/CFA/HKMTB (n=7), or MOG/CFA (n=13) and 
analyzed 30 days later. (A,B) Sorted CD4+ T cells were restimulated with MOG35-55, and 
the cytokine concentrations were determined by ELISA. Statistical significance was 
determined by Student’s t-test. NS P>0.05, * P<0.05, and ** P<0.01. 
 
Fig. 3. Splenocytes from HKMTB-immunized PD-1-/- RAG2-/- mice facilitate Th17 
induction in vitro. Splenocytes from non-immunized or HKMTB/CFA-immunized PD-
1+/+ RAG2-/- and PD-1-/- RAG2-/- mice (C57BL/6 background) were cultured with naive 
CD4+ T cells from OTII TCR Tg mice in the presence of OVA323–339  (5 µg/ml) under 
conditions indicated. Development of the IL-17-producing (A) or IFN-γ-producing (B) 
CD4+ T cells were examined by intracellular cytokine staining. Essentially same data 
were obtained from experiments immunizing PD-1-/- RAG2-/- mice (BALB/c 
background) and naïve CD4+ cells from DO11.10 TCR Tg mice (BALB/c background) 
(Fig. S2). 
 
Fig. 4. Non-lymphocyte population of PD-1-/- mice cause enhanced Th17 
development and exacerbation of EAE.  (A) Lethally irradiated C57BL/6 mice were 
reconstituted by bone marrow transplantation and adoptive transfer of CD4+ cells as 
indicated. Mice were immunized with MOG/CFA/HKMTB and the EAE score evaluated. 
Data presented are combined from two independent experiments (total 18 mice included 
in each group) (mean±SEM). Statistical significance was determined by Student’s t-test 
(* P<0.05, and ** P<0.01). (B) CD4+ T cells were harvested at day 30 and re-stimulated 
by MOG35-55 as indicated in materials and methods. IL-17 and IFN-γ were measured. 
Each point represents an individual mouse, with the black bar indicating the mean value. 
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Mice reconstituted with PD-1-/- RAG2-/- BM showed significantly higher IL-17 than PD-
1+/+ RAG2-/- counterpart by one-tailed Student’s t-test. (* P=0.04) 
 
Fig. 5. CD11b+ cells from PD-1-/- mice efficiently induce Th17 cell development upon 
HKMTB stimulation CD11b+ cells were purified from the splenocytes of PD-1+/+ and 
PD-1-/- mice (A) or PD-1+/+ RAG2-/- and PD-1-/- RAG2-/- mice (C) (all in C57BL/6 
background) and were either untreated (ctrl), or stimulated by HKMTB (10 and 100 
µg/ml). Three days later, the stimulated cells were co-cultured with CD4+ T cells from 
OTII TCR Tg mice in the presence of OVA323–339  (5 µg/ml) for 4 days. IL-17-producing 
OTII+ CD4+ T cells (PD-1+/+) were quantified by intracellular cytokine staining. (B) 
Summary of the data shown in (A). Note that CD11b- cells from PD-1+/+ and PD-1-/- mice 
did not induce Th17 by two independent experiments. Data shown of CD11b+ cells are 
mean±SD from six independent experiments (for ctrl and HKMTB 100 µg/ml condition) 
and four experiments (for HKMTB 10 µg/ml condition). Statistical significance was 
determined by Student’s t-test. * P<0.05 and ** P<0.01. 
 
Fig. 6. Enhanced production of IL-6 by CD11b+ cells from PD-1-/- mice causes strong 
Th17 development CD11b+ cells purified from the splenocytes from PD-1+/+ and PD-1-/- 
mice (C57BL/6 background) were either untreated (ctrl) or stimulated with HKMTB (10 
and 100 µg/ml), or HKLM (10 and 100 µg/ml). Three days later, the production of IL-6 
(A), TNF-α (B), and IL-10 (C) was evaluated. Data presented are combined from three 
independent experiments (mean±SD). Significance was determined by Student’s t-test. * 
P<0.05. (D) HKMTB-stimulated CD11b+ cells were co-cultured in the presence of 
OTII+CD4+ T cells and OVA323–339 together with rat IgG (200 ng/ml) or anti-IL-6R (as 
shown) under neutral condition for 4 days. IL-17-producing OTII+ CD4+ T cells were 
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Fig. S1. Increased infiltrating cells to central nervous system in PD-1-/- EAE mice. PD-1+/+ (n=9) 
and PD-1-/- mice (n=8) were immunized by MOG/CFA/HKMTB and analyzed 8 days later. 
Unimmunized PD-1+/+ mice (n=3) were used as control. Cells were prepared as described in 
“supplementary methods” and referred to as total cells. (A) Data shown are representative FACS 
analysis of three independent experiments (B) Calculated absoulute numbers of each population was    .        
shown. Statistical significance was determined by two tailed Student’s t-test. * * P<0.01, * P<0.05.
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Fig. S2. Splenocytes from HKMTB-immunized PD-1-/- RAG2-/- mice facilitate Th17 induction in 
vitro. Splenocytes from non-immunized or HKMTB/CFA-immunized PD-1+/+ RAG2-/- and PD-1-/-
RAG2-/- mice (BALB/c background) were cultured with naive CD4+ T cells from DO11.10 TCR Tg
mice in the presence of OVA323–339 (5 g/ml) under conditions indicated. Development of the IL-17-
producing or IFN--producing CD4+ T cells were examined by intracellular cytokine staining. Data 
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Fig. S3. Splenocytes from HKMTB-immunized, RAG2 sufficient PD-1-/- mice
facilitate Th17 induction in vitro Splenocytes from non immunized or HKMTB/CFA immunized
                              
skewing condition
    .       
PD-1+/+ and PD-1-/- mice (C57BL/6 background) were incubated with naive CD4+ T cells from OTII 
TCR Tg mice in the presence of OVA (5 g/ml) under no skew, neutral, Th17 skewing, or Th1 
skewing conditions. Four days later, the IL-17-producing (A) or IFN--producing (B) CD4+ T cells 
were quantified by intracellular cytokine staining. Data presented are combined from two 
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Fig. S4. Dendritic cells are not involved in the HKMTB treated CD11b+-mediated Th17 
polarization. FACS Aria sorted CD11b+ and DC (CD11b+ CD11c+)  cells from splenocytes of PD-
1+/+ and PD-1-/- mice are treated by either ctrl (no stimulation) or HKMTB (100 g/ml) and used in 
antigen-specific Th skewing in vitro. IL-17-producing OTII+ CD4+ T cells were quantified by 
intracellular cytokine staining. Data shown are representative of two independent experiments.
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Supplementary Information
Peptides and FACS antibodies
Mouse myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) 
and chicken OVA323–339 peptide (ISQAVHAAHAEINEAGR) were synthesized by MBL (Nagoya, Japan).
Incomplete Freund’s adjuvant (IFA; Difco, Detroit, MI), complete Freund’s adjuvant (CFA; Difco), heat 
killed Mycobacterium tuberculosis H37RA (HKMTB; Difco), heat killed listeria monocytogenes
(HKLM; InvivoGen, San Diego, CA), and pertussis toxin (PTX; List Biological Laboratories, Campbell, 
CA) were used. Antibodies (Abs) for FACS analysis [anti-CD4 (RM4-5), anti-DO11.10 TCR (KJ1-26), 
anti-TCRV2 (B20.1), anti-IFN- (XMG1.2), anti-IL-17 (TC11.18H10), anti-CD45 (30-F11), anti-CD11b 
(M1/70) and anti CD11c (N418)] were from eBioscience (San Diego CA) or Biolegend (San Diego CA)  -      ,    , . 
Recombinant IL-6 and IL-12 were from Wako (Osaka, Japan), and human TGF-1 was from Miltenyi
Biotec (Tokyo, Japan). Neutralizing anti-IL-4 (1D11) and anti-IFN-XMG1.2) antibodies were from 
Thermo Scientific (Yokohama, Japan).
Isolation of mononuclear cells from mouse brain      
Brain was  harvested and cells were prepared as previously described (1). Briefly, the tissue was minced, 
enzyme-digested and then subjected for percoll gradient separation. The cells in interface between 37% 
and 70% percoll were recovered, referred to as total cells and subjected for FACS analysis.
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